These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24277784)

  • 1. Pre-existing cross-reactive antibodies to avian influenza H5N1 and 2009 pandemic H1N1 in US military personnel.
    Pichyangkul S; Krasaesub S; Jongkaewwattana A; Thitithanyanont A; Wiboon-Ut S; Yongvanitchit K; Limsalakpetch A; Kum-Arb U; Mongkolsirichaikul D; Khemnu N; Mahanonda R; Garcia JM; Mason CJ; Walsh DS; Saunders DL
    Am J Trop Med Hyg; 2014 Jan; 90(1):149-52. PubMed ID: 24277784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti N1 cross-protecting antibodies against H5N1 detected in H1N1 infected people.
    Frobert E; Bouscambert-Duchamp M; Escuret V; Mundweiler S; Barthélémy M; Morfin F; Valette M; Gerdil C; Lina B; Ferraris O
    Curr Microbiol; 2010 Jul; 61(1):25-8. PubMed ID: 20033691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial.
    Bethell D; Saunders D; Jongkaewwattana A; Kramyu J; Thitithayanont A; Wiboon-ut S; Yongvanitchit K; Limsalakpetch A; Kum-Arb U; Uthaimongkol N; Garcia JM; Timmermans AE; Peiris M; Thomas S; Engering A; Jarman RG; Mongkolsirichaikul D; Mason C; Khemnu N; Tyner SD; Fukuda MM; Walsh DS; Pichyangkul S
    PLoS One; 2013; 8(3):e59674. PubMed ID: 23555741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of serum neutralization antibodies against seasonal influenza A strain H3N2 and the emerging strains 2009 H1N1 and avian H5N1.
    Zhang R; Rong X; Pan W; Peng T
    Scand J Infect Dis; 2011 Mar; 43(3):216-20. PubMed ID: 21142624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics, Longevity, and Cross-Reactivity of Antineuraminidase Antibody after Natural Infection with Influenza A Viruses.
    Changsom D; Jiang L; Lerdsamran H; Iamsirithaworn S; Kitphati R; Pooruk P; Auewarakul P; Puthavathana P
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients.
    Kositanont U; Wongsurakiat P; Pooruk P; Maranetra N; Puthavathana P
    Viral Immunol; 2010 Jun; 23(3):329-34. PubMed ID: 20565296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
    Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
    BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Antibodies Induced by Vaccination with 4 Kinds of Avian Influenza H5N1 Pre-Pandemic Vaccines.
    Ohshima N; Iba Y; Kubota-Koketsu R; Yamasaki A; Majima K; Kurosawa G; Hirano D; Yoshida S; Sugiura M; Asano Y; Okuno Y; Kurosawa Y
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus.
    Lemaitre M; Leruez-Ville M; De Lamballerie XN; Salez N; Garrone P; Fluckiger AC; Klatzmann D; Carrat F
    Clin Microbiol Infect; 2011 May; 17(5):732-7. PubMed ID: 20731679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine.
    Qiu C; Huang Y; Wang Q; Tian D; Zhang W; Hu Y; Yuan Z; Zhang X; Xu J
    Clin Infect Dis; 2012 Jan; 54(1):17-24. PubMed ID: 22052887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus.
    Van Reeth K; Braeckmans D; Cox E; Van Borm S; van den Berg T; Goddeeris B; De Vleeschauwer A
    Vaccine; 2009 Oct; 27(45):6330-9. PubMed ID: 19840669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.
    Ahmed MS; Jacques LC; Mahallawi W; Ferrara F; Temperton N; Upile N; Vaughan C; Sharma R; Beer H; Hoschler K; McNamara PS; Zhang Q
    Antiviral Res; 2015 Feb; 114():106-12. PubMed ID: 25513756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine.
    Nakayama M; Shichinohe S; Itoh Y; Ishigaki H; Kitano M; Arikata M; Pham VL; Ishida H; Kitagawa N; Okamatsu M; Sakoda Y; Ichikawa T; Tsuchiya H; Nakamura S; Le QM; Ito M; Kawaoka Y; Kida H; Ogasawara K
    PLoS One; 2013; 8(12):e82740. PubMed ID: 24376571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infection with 2009 H1N1 influenza virus primes for immunological memory in human nose-associated lymphoid tissue, offering cross-reactive immunity to H1N1 and avian H5N1 viruses.
    Mahallawi WH; Kasbekar AV; McCormick MS; Hoschler K; Temperton N; Leong SC; Beer H; Ferrara F; McNamara PS; Zhang Q
    J Virol; 2013 May; 87(10):5331-9. PubMed ID: 23468498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
    van der Velden MV; Geisberger A; Dvorak T; Portsmouth D; Fritz R; Crowe BA; Herr W; Distler E; Wagner EM; Zeitlinger M; Sauermann R; Stephan C; Ehrlich HJ; Barrett PN; Aichinger G
    Clin Vaccine Immunol; 2014 Jun; 21(6):867-76. PubMed ID: 24739978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
    Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
    PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
    Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
    Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.
    Marcelin G; DuBois R; Rubrum A; Russell CJ; McElhaney JE; Webby RJ
    PLoS One; 2011; 6(10):e26335. PubMed ID: 22039464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.